BC Week In Review | Dec 9, 2013
Company News

Teva neurology, infectious and ophthalmic news

Teva said it has approved 15 new therapeutic entity (NTE) programs for development, including four abuse-deterrent opioids, four fixed-dose combinations of antiretrovirals for HIV, a once-daily fixed combination of a prostaglandin agonist and beta blocker...
BC Extra | Dec 5, 2013
Company News

Teva provides details of NTEs in program update

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said it has approved 15 new therapeutic entity (NTE) programs for development, including four abuse-deterrent opioids, four fixed-dose combinations of antiretrovirals for HIV, a once-daily fixed combination of a prostaglandin...
BioCentury | Nov 4, 2013
Strategy

Teva blinks

With a deeply experienced CEO known for executing large, transformational deals, Teva Pharmaceutical Industries Ltd. had the chance to do something disruptive. But after the abrupt departure of President and CEO Jeremy Levin last Wednesday,...
BioCentury | Dec 10, 2012
Strategy

Teva's new roadmap

Following a six-month review, Teva Pharmaceuticals Industries Ltd. 's new management is drawing a clean line with the company's past by refocusing R&D investment on key growth drivers in complex and combination generics and branded...
BC Innovations | Nov 13, 2008
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neuropathy Protein kinase, cAMP-dependent, catalytic, a (PRKACA; PKACA); protein kinase, X-linked (PRKX); patatin-like phospholipase domain containing 6 (PNPLA6; NTE) Studies in...
BC Innovations | May 22, 2008
Targets & Mechanisms

So FAAH, So Good, Maybe

A paper in Nature Chemical Biology describes the potent analgesic effect of a class of organophosphorus compounds that enhances cannabinoid receptor activity. 1 Unlike pain treatments based on agonizing cannabinoid receptors with compounds such as...
Items per page:
1 - 6 of 6